Promethazine hydrochloride 100mg/4ml

Solution for injection

Promethazine Hydrochloride Injection is indicated for the following conditions:
1. Amelioration of allergic reactions to blood or plasma.
2. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute
symptoms have been controlled.
3. For other uncomplicated allergic conditions of the immediate type when oral therapy is
impossible or contraindicated.
4. For sedation and relief of apprehension and to produce light sleep from which the patient can be
easily aroused.
5. Active treatment of motion sickness.
6. Prevention and control of nausea and vomiting associated with certain types of anaesthesia and
surgery.
7. As an adjunct to analgesics for the control of postoperative pain.
8. Preoperative, postoperative, and obstetric (during labour) sedation.
9. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery,
and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an
adjunct to anaesthesia and analgesia

Route of administration: Intramuscular or intravenous (after dilution)
The usual dose is 25 - 50 mg by deep intramuscular injection, or, in emergency, by slow intravenous injection after dilution of the 2.5% solution to 10 times its volume with water for injections immediately before use.
Maximum parenteral dose 100 mg.
Elderly:No specific dosage recommendations.
Children:6.25 - 12.5 mg for children from 5 - 10 years by deep intramuscular injection. Not for use in children under 2 years of age

Famotidine 20mg/2ml

Solution for Injection

Supplied as a concentrated solution for intravenous injection, is intended for intravenous use only.  Indicated in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in patients who are unable to take oral medication for the following conditions:
1. Short term treatment of active duodenal ulcer.  Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks.  Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than 8 weeks.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.  Controlled studies in adults have not extended beyond one year.
3. Short term treatment of active benign gastric ulcer.  Most adult patients heal within 6 weeks.  Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks.
4. Short term treatment of gastroesophageal reflux disease (GERD).  Famotidine is indicated for short term treatment of patients with symptoms of GERD. Famotidine is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

For intravenous injection or infusion.

Levof BFS 250mg 

Solution for injection

-Pneumonia: nosocomial and community acquired 
-Acute bacterial sinusitis
-Acute bacterial exacerbation of chronic bronchitis
-Skin and skin structure infections: complicated and uncomplicated
-Chronic bacterial prostatitis
-Urinary tract infections: complicated and uncomplicated
-Acute pyelonephritis
-Inhalational anthrax, post-exposure

Levof BFS 250mg solution for infusion is administered by slow intravenous infusion once or twice daily. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen. 

Sodium hyaluronate 10 mg/ml

Solution for injection

Indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics, eg, acetaminophen.

The usual dosage is 2.5 ml of Hyaza - BFS (25 mg of sodium hyaluronate) once a week for 3-5 weeks. Treatment can be repeated, usually, from 6 to 12 months. It is possible to conduct treatment at the same time with more than 1 joint position.
Hyaza - BFS is injected directly into the joint
If there is phenomenon of joint effusion, it is necessary to aspirate before injection.
For the first 48 hours after injection, patients should rest, avoid strong physical activity in the area where the injection was given.

Ciprofloxacin 200mg/10ml

Solution for injection

Ciprofloxacin is indicated for severe infections where conventional antibiotics no longer work to prevent the development of ciprofloxacin-resistant bacteria.

The solution for infusion should be administered over an infusion period of 60 minutes. 
The dosage is determined by the indication, the severity and the site of the infection, the susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, in children and adolescents the body weight.
The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course.
After intravenous initiation of treatment, the treatment can be switched to oral treatment with tablet or suspension if clinically indicated at the discretion of the physician. IV treatment should be followed by oral route as soon as possible.
 

Linezolid 600mg/10ml

Concentrated solution for injection

Line BFS is used for treating these infections:

- Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae.
- Community-acquired pneumonia caused by Streptococcus pneumoniae, or Staphylococcus aureus (methicillin-susceptible isolates only)
- Complicated and uncomplicated skin and skin structure infections such as diabetic foot infections.
- Vancomycin-resistant Enterococcus faecium infections.
 

Line-bfs could be lilued and using for infusion
Diluted solvent: Sterile sodium Cloride 0.9 % for injection, and glucose 5%
Swist Line- BFS 600 mg ( as Linezolid), diluting into 300 ml- 500 ml solvent and infusion. The diluting solution should be storaged in sterile condition, in hermetic packing, 2 °C – 8 °C  and using within 8 hours
Infusion in 30 minutes- 120 minutes
Unmixed to any others compounds to infusion

Tranexamic acid 250mg/5ml

Solution for injection

Prevention and treatment of haemorrhages due to general or local fibrinolysis in adults and children from one year

The administration is strictly limited to slow intravenous injection.

Lidocaine hydrochloride monohydrate 200mg/10ml.

Solution for injection.

Lidocaine is a local anaesthetic of the amide group. The injectable form has a wide range of applications for nerve blockade. It can be used by percutaneous infiltration; to block a major nerve plexus such as the brachial; for epidural anaesthesia; for intravenous regional analgesia.

The dosage should be adjusted according to the response of the patient and the site of administration. The lowest concentration and smallest dose producing the required effect should be given. The maximum dose for healthy adults should not exceed 200mg.
Children and elderly or debilitated patients require smaller doses, commensurate with age and physical status.

Hydroxocobalamin 5mg/ml

Solution for injection

Blood diseases:
- Idiopathic anemia or gastrectomy. 
- Spru's disease, diarrhea and other diseases of vitamin B12 deficiency due to poor absorption. 
- Absorption decreases after partial gastric bypass and gastrointestinal distress syndrome as well as rare cases of pregnancy-induced anemia. 
- Support treatment with aminosalicylate because it reduces the absorption of B12.

Addisonian pernicious anaemia and other macrocytic anaemias without neurological involvement:
Initially:    250 micrograms to 1000 micrograms intramuscularly on alternate days for one or two weeks then 250 micrograms weekly until blood count is normal.
Maintenance:    1000 micrograms every two or three months.
Addisonian pernicious anaemia and other macrocytic anaemias with neurological involvement:
Initially:    1000 micrograms on alternate days as long as improvement continues.
Maintenance:    1000 micrograms every two months.
Prophylaxis of macrocytic anaemias associated with vitamin B12 deficiency resulting from gastrectomy, ileal resection, certain ma/absorption states and vegetarianism: 1000 micrograms every two or three months.
Tobacco amblyopia and Leber's optic atrophy:
Initially:    1000 micrograms daily by intramuscular injection for two weeks then twice weekly as long as improvement is maintained.
Maintenance:    1000 micrograms every three months or as required.

Salbutamol (as salbutamol sulfate) 5mg/5ml

Solution for Injection

Geumi Injection is indicated in adults and adolescents.
Geumi Injection provides short-acting (4-6 hour) bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction. It is indicated for the relief of severe bronchospasm.

Geumi Injection may be administered by the subcutaneous, intramuscular or intravenous route, under the direction of a physician.
Adults:
Subcutaneous route: 500 micrograms (8 micrograms/kg body weight) and repeated every four hours as required.
Intramuscular route: 500 micrograms (8 micrograms/kg body weight) and repeated every four hours as required.
Slow intravenous injection:
250 micrograms (4 micrograms/kg bodyweight) injected slowly. If necessary the dose may be repeated.
The use of Ventolin Injection 500 micrograms in 1ml (500 micrograms/ml, for intravenenous administration may be facilitated by dilution to 10ml with Water for Injection BP (final concentration of 50 micrograms/ml) and 5mls of the diluted preparation (250 micrograms/5ml) administered by slow intravenous injection.
Paediatric Population
The safety and efficacy of Ventolin Injection in children under the age of 12 has not been established. From the available data no recommendation on posology can be made.
Children aged 12 years and over: Dose as per adult population

Digoxin 0.25 mg/ml

Solution for injection

Indicated in the management of chronic cardiac failure, systolic dysfunction, ventricular dilatation, cardiac failure is accompanied by atrial fibrillation.
The management of certain supraventricular arrhythmias, particularly chronic atrial flutter and fibrillation.

Posology:
The dose of digoxin for each patient has to be tailored individually according to age, lean body weight and renal function.
Suggested doses are intended only as an initial guide.
In cases where cardiac glycosides have been taken in the preceding two weeks the recommendations for initial dosing of a patient should be reconsidered and a reduced dose is advised.
The difference in bioavailability between injectable digoxin and oral formulations must be considered when changing from one dosage form to another. For example if patients are switched from oral to the I.V. formulation the dosage should be reduced by approximately 33%.
Adults and paediatric populations over 10 years
Parenteral loading:
Parenteral loading should only be used in patients who have not been given cardiac glycosides within the preceding two weeks.
The total loading dose of parenteral digoxin is 500 to 1000 micrograms (0.5 to 1.0 mg) depending on age, lean body weight and renal function. The total loading dose should be administered in divided doses with approximately half of the total dose given as the first dose and further fractions of the total dose given at intervals of four to eight hours. An assessment of clinical response should be performed before giving each additional dose.
Each dose should be given by I.V. infusion (see Method of Administration, below) over 10 to 20 mins.

Elderly
The possibility of reduced renal function and lower lean body mass should be taken into account when dealing with elderly patients. If necessary, the dosage should be reduced and adjusted to the changed pharmacokinetics to prevent elevated serum dioxin levels and the risk of toxicity. The serum dioxin levels should be checked regularly and hypokalaemia should be avoided.
Renal impairment
The dosing recommendations should be reconsidered if patients are elderly or there are other reasons for the renal clearance of digoxin being reduced. A reduction in both initial and maintenance doses should be considered (see Section 4.4).
Method of administration:
Dilution of digoxin injection:
Digoxin injection can be administered undiluted or diluted with a 4-fold or greater volume of 0.9% Sodium Chloride Injection, 0.18 % Sodium Chloride/4% Glucose Injection or 5% Glucose Injection. A 4-fold volume of diluent equates to adding one 2 ml ampoule of digoxin to 6 ml of injection solution. The use of less than a 4-fold volume of diluent could lead to precipitation of digoxin.
Digoxin injection, when diluted in the ratio of 1 to 250 is known to be compatible with the following infusion solutions and stable for up to 48 h at room temperature (20 to 25 °C):
• Sodium Chloride I.V. Infusion, B.P., 0.9 % w/v.
• Sodium Chloride (0.18 % w/v) and Glucose (4 % w/v) I.V. Infusion, B.P.
• Glucose I.V. Infusion, B.P., 5 % w/v.
A ratio of 1 to 250 can be obtained for example by diluting one 2 ml ampoule with 500 ml of infusion solution.
Dilution should be carried out either under full aseptic conditions or immediately before use. Any unused solution should be discarded (see Section 6.6).
Administration of digoxin injection:
Each dose should be given by I.V. infusion over 10 to 20 mins.
The total loading dose should be administered in divided doses with approximately half of the total dose given as the first dose and further fractions of the total dose given at intervals of four to eight hours. An assessment of clinical response should be performed before giving each additional dose.
The I.M. route is painful and is associated with muscle necrosis. This route cannot be recommended.
Rapid I.V. injection can cause vasoconstriction producing hypertension and/or reduced coronary flow. A slow injection rate is therefore important in hypertensive heart failure and acute myocardial infarction.

Propranolol hydrocloride 1mg/ml

Solution for injection.

Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring
under anesthesia.
1. Supraventricular arrhythmias
2. Ventricular tachycardias
3. Tachyarrhythmias of digitalis intoxication
4. Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia

For intravenous administration.